GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Other Current Liabilities

KAPA (Kairos Pharma) Other Current Liabilities : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Other Current Liabilities?

Kairos Pharma's other current liabilities for the quarter that ended in Mar. 2025 was $0.00 Mil.


Kairos Pharma Other Current Liabilities Historical Data

The historical data trend for Kairos Pharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Other Current Liabilities Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Liabilities
- - - - -

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kairos Pharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.


Kairos Pharma Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kairos Pharma Business Description

Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.